China Nicotine Replacement Therapy Market Overview,2030

The nicotine replacement therapy (NRT) market in China has evolved within the context of the world’s largest smoking population, where more than 300 million adults smoke, representing roughly 25% of the global total. Historically, smoking has been deeply embedded in Chinese culture, often linked to business interactions and social rituals, which slowed the development of cessation initiatives. NRT products such as nicotine patches, gums, and lozenges were introduced in China in the late 1990s through multinational firms such as Johnson & Johnson (Nicorette) and GlaxoSmithKline (NiQuitin). However, adoption remained limited for years due to low awareness of smoking-related health risks, weak anti-tobacco enforcement, and relatively high costs compared to cigarettes. A turning point came in the mid-2010s when China intensified tobacco control policies, particularly following its 2015 commitment to the WHO Framework Convention on Tobacco Control (FCTC). Cities like Beijing and Shanghai introduced comprehensive indoor smoking bans, and public health campaigns began to emphasize cessation. By the late 2010s, NRT started gaining visibility in urban hospitals and pharmacies, though penetration remained concentrated in first-tier cities. As of 2024, the Chinese NRT market is estimated at over USD 500 million, but its potential remains vastly underdeveloped relative to smoking prevalence. While public health authorities recognize NRT as a cessation tool, there is no nationwide reimbursement, meaning purchases are largely out-of-pocket. This creates significant disparities between urban and rural adoption. Overall, China’s NRT market is in a nascent but promising stage, driven by urbanization, health awareness, and gradual policy shifts.

According to the research report ""China Nicotine Replacement Therapy Market Overview, 2030,"" published by Bonafide Research, the China Nicotine Replacement Therapy market is anticipated to grow at 13.06% CAGR from 2025 to 2030.China’s NRT market offers enormous opportunities given its vast smoking base and rising government focus on public health. Regulatory oversight is managed by the National Medical Products Administration (NMPA), which classifies NRT products as pharmaceuticals, requiring strict safety and efficacy approvals. Unlike many Western countries, NRT is not reimbursed under China’s national health insurance, creating affordability barriers for lower-income groups. However, urban demand is rising as health consciousness increases, particularly among younger professionals and middle-class smokers in Beijing, Shanghai, and Guangzhou. Strategic opportunities lie in expanding affordable generics, developing localized NRT brands to reduce reliance on imports, and integrating NRT into national cessation programs. Market trends show growing interest in fast-acting delivery formats, such as sprays and lozenges, as Chinese consumers favor convenience and discreet use. Another trend is the integration of NRT with digital health platforms: several hospitals and health apps are piloting “smoking cessation packages” combining NRT with mobile-based behavioral therapy. Yet, competition is intensifying from electronic cigarettes and heated tobacco products, which have gained traction among younger demographics despite strict regulatory crackdowns. China’s 2022 regulation on e-cigarettes banned flavored vapes and required licensing under state monopoly control, opening indirect opportunities for NRT by limiting alternatives. Strategic recommendations include partnering with hospitals and digital platforms for integrated cessation programs, advocating for partial insurance coverage to improve affordability, and emphasizing NRT’s medical validation over consumer-driven alternatives. Given China’s stated goal to reduce smoking prevalence to below 20% by 2030, NRT adoption is expected to accelerate if affordability and accessibility barriers are addressed.

China’s nicotine alternatives market is highly segmented across NRT, e-cigarettes, and heat-not-burn (HnB) products, with each category serving distinct consumer segments. NRT remains the only clinically validated cessation method, with gums and patches leading sales through pharmacies and hospitals. Brands like Nicorette dominate, but domestic generics are gradually emerging, offering lower-cost alternatives to increase accessibility. Despite clinical validation, NRT adoption is modest compared to consumer-driven alternatives. E-cigarettes, particularly disposable vapes, have experienced explosive growth in China over the past decade, with more than 20 million adult users reported before the 2022 regulatory crackdown. Brands like RELX led this expansion, especially among urban youth, who viewed vaping as modern, fashionable, and cheaper than NRT. Heat-not-burn products, particularly Philip Morris International’s IQOS, entered China through gray-market imports in the mid-2010s and gained popularity among affluent consumers in major cities. However, due to China’s tobacco monopoly system, official distribution is tightly controlled, with the state-owned China National Tobacco Corporation (CNTC) actively developing its own HnB products to capture market share. These alternatives compete directly with NRT for smoker transition. While NRT appeals primarily to health-conscious individuals seeking medically validated cessation, e-cigarettes and HnB products dominate consumer perception as convenient and socially integrated alternatives. The future of this segmentation will depend on regulatory enforcement: as e-cigarette restrictions tighten and CNTC promotes its own HnB products, NRT manufacturers have a window of opportunity to reposition NRT as the most reliable cessation tool, particularly if integrated with public health initiatives and localized awareness campaigns.


China’s NRT market is currently dominated by over-the-counter (OTC) sales, reflecting consumer preference for convenience and self-directed quit attempts. Pharmacies in urban centers are the primary distribution point, offering gums, patches, lozenges, and limited spray formats without requiring prescriptions. This OTC structure appeals to younger and middle-class consumers who value privacy and accessibility. Prescription-based sales exist but are concentrated in hospital settings, where doctors may recommend NRT as part of structured cessation programs. However, because NRT is not covered under China’s national health insurance scheme, prescription uptake remains limited, particularly outside major cities. Prescription-driven sales are further hindered by low awareness among both patients and physicians, as smoking cessation has not historically been prioritized within routine medical practice. Recent initiatives in Beijing and Shanghai hospitals, which integrate counseling with NRT prescriptions, signal gradual change, but scale remains limited. Strategic opportunities lie in expanding prescription-based channels by embedding NRT into nationwide cessation guidelines and advocating for partial insurance coverage to enhance affordability. In the current market, OTC sales dominate due to consumer-driven demand, but the long-term growth of prescription-based sales depends on policy reform and integration with China’s public healthcare system. Given the government’s increasing commitment to tobacco control and chronic disease reduction, prescription-based NRT could see rapid expansion over the next decade if reimbursement and physician training programs are implemented.

Distribution of NRT in China is still led by offline channels, particularly the extensive network of more than 200,000 pharmacies, as well as hospitals and specialized cessation clinics. Pharmacies remain the backbone of sales, offering OTC products and serving as trusted points of access for consumers. Hospitals play an important role in prescription-based sales, especially in major cities where smoking cessation clinics have been established. Offline channels benefit from consumer trust and regulatory oversight, ensuring authenticity in a market often challenged by counterfeit concerns. Online distribution has grown rapidly over the past five years, fueled by China’s advanced e-commerce ecosystem. Platforms such as JD Health, Alibaba’s Tmall, and Ping An Good Doctor increasingly sell NRT products, offering home delivery and integration with telemedicine services. This trend was accelerated during the COVID-19 pandemic, when many consumers shifted to online health solutions. Younger, digitally engaged consumers are driving demand for online channels, particularly for discreet products like gums and lozenges. However, regulatory oversight remains strict, with the NMPA closely monitoring online pharmaceutical sales to ensure compliance and safety. While online channels currently represent a smaller share of the market compared to offline, they are expected to grow rapidly, potentially reaching parity over the next decade as digital health adoption expands. Hybrid distribution models, combining online convenience with offline pharmacy counseling, represent a major opportunity in China’s NRT landscape. Overall, the dual-channel structure reflects China’s healthcare evolution, where offline trust and online convenience increasingly coexist

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Nicotine Replacement Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Nicotine Replacement Therapy
• E-cigarettes
• Heat-not-burn tobacco products
By Nicotine Replacement Therapy
• Nicotine Gums
• Nicotine Lozenges
• Nicotine Nasal Sprays
• Nicotine Pouches
• Others (Nicotine Patches, Nicotine Inhalers & Others)
By Sales Type
• Over-the-Counter (OTC)
• Prescription-Based

By Distribution Channel
• Offline
• Online
Show more